An LC-MS/MS Method for Absolute Quantification of Nivolumab in Human Plasma: Application to Clinical Therapeutic Drug Monitoring

DOI: 10.1097/ftd.0000000000000558
Therapeutic Drug Monitoring, 2018, 40, 716-724.

#	Paper	IF	Citations
17	Quantitative LC-MS/MS method for nivolumab in human serum using IgG purification and immobilized tryptic digestion. *Analytical Methods*, **2020**, 12, 54-62	3.2	6
16	Bottom-up sample preparation for the LC-MS/MS quantification of anti-cancer monoclonal antibodies in bio matrices. *Bioanalysis*, **2020**, 12, 1405-1425	2.1	6
15	Development and Validation of an LC-MS-Based Quantification Assay for New Therapeutic Antibodies: Application to a Novel Therapy against Herpes Simplex Virus. *ACS Omega*, **2020**, 5, 24329-24339	3.9	2
14	Pharmacokinetics/Pharmacodynamic (PK/PD) relationship of therapeutic monoclonal antibodies used in oncology: what's new?. *European Journal of Cancer*, **2020**, 128, 103-106	7.5	5
13	Dose and therapy individualization in cancer chemotherapy. *Handbook of Analytical Separations*, **2020**, 291-319	0.7	1
12	Quantification of nivolumab in human plasma by LC-MS/HRMS and LC-MS/MS, comparison with ELISA. *Talanta*, **2021**, 224, 121889	6.2	10
11	Approaching sites of action of drugs in clinical pharmacology: New analytical options and their challenges. *British Journal of Clinical Pharmacology*, **2021**, 87, 858-874	3.8	5
10	Use of an alternative signature peptide during development of a LC-MS/MS assay of plasma nivolumab levels applicable for multiple species. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2021**, 1162, 122489	3.2	2
9	Dosage of anti-PD-1 monoclonal antibodies: a cardinal open question. *Clinical and Translational Oncology*, **2021**, 23, 1511-1519	3.6	1
8	Pharmacokinetics and clinical outcomes of nivolumab administered every 4 weeks in patients with advanced non-small-cell lung cancer: A four-case pilot study. *Respiratory Investigation*, **2021**, 59, 545-549	3.4	1
7	Evaluating the efficacy and safety of immune checkpoint inhibitors by detecting the exposure-response: An inductive review. *International Immunopharmacology*, **2021**, 97, 107703	5.8	0
6	Cross-Validation of a Multiplex LC-MS/MS Method for Assaying mAbs Plasma Levels in Patients with Cancer: A GPCO-UNICANCER Study. *Pharmaceuticals*, **2021**, 14,	5.2	1
5	Construction of Quantitative Analysis Workflow for Determination of Serum Concentrations of Monoclonal Antibody Drugs Aiming to Promote Therapeutic Drug Monitoring in Clinical Practice. *Japanese Journal of Clinical Pharmacology and Therapeutics*, **2020**, 51, 161-166	0	
4	Development and validation of a UPLC-MS/MS method to quantitate anti-PD1 monoclonal antibody (Toripalimab), and comparison with electrochemiluminescence immunoassay. *Journal of Pharmaceutical and Biomedical Analysis*, **2021**, 209, 114515	3.5	0
3	Research Progress on Quantification Methods of Drug Concentration of Monoclonal Antibodies. *Current Pharmaceutical Analysis*, **2022**, 18,	0.6	
2	Optimized sample pre-treatment procedure for the simultaneous UPLC-MS/MS quantification of ipilimumab, nivolumab, and pembrolizumab in human serum.. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2022**, 1196, 123215	3.2	0
1	Combined use of UV and MS data for ICH Stability-Indication Method: Quantification and isoforms identification of intact nivolumab. **2022**, 182, 107896		0